Phase 1 Study of the Irreversible FGFR Inhibitor Futibatinib in Japanese Patients With Advanced Solid Tumors: Updated Dose Expansion Results and Activity in Gastric Cancer

**Background**

- **FGFR** aberrations in cancer: FGFR aberrations are common in various cancers, including gastric cancer.
- **FGFR2** amplification is a frequent event in gastric cancer and other solid tumors with FGFR/FGF signaling.
- **FGFR2** amplification levels (CNV <4 or ≥4 and CNV <10 or ≥10) are clinically relevant.
- **FGFR2** amplification is associated with poor prognosis in gastric cancer.
- **FGFR2** amplification levels (CNV <4 or ≥4 and CNV <10 or ≥10) are clinically relevant.
- **FGFR2** amplification is associated with poor prognosis in gastric cancer.

**Methods**

- **FGFR** aberrations were assessed using **FGFR** copy number value (CNV) and **FGFR2** amplification levels.
- **FGFR2** amplification levels were calculated using **FGFR** copy number value (CNV) and **FGFR2** amplification levels.
- **FGFR2** amplification levels were calculated using **FGFR** copy number value (CNV) and **FGFR2** amplification levels.
- **FGFR2** amplification levels were calculated using **FGFR** copy number value (CNV) and **FGFR2** amplification levels.

**Results**

- **FGFR2** amplification levels (CNV <4 or ≥4 and CNV <10 or ≥10) are clinically relevant.
- **FGFR2** amplification levels (CNV <4 or ≥4 and CNV <10 or ≥10) are clinically relevant.
- **FGFR2** amplification levels (CNV <4 or ≥4 and CNV <10 or ≥10) are clinically relevant.
- **FGFR2** amplification levels (CNV <4 or ≥4 and CNV <10 or ≥10) are clinically relevant.

**Conclusions**

- **FGFR2** amplification levels (CNV <4 or ≥4 and CNV <10 or ≥10) are clinically relevant.
- **FGFR2** amplification levels (CNV <4 or ≥4 and CNV <10 or ≥10) are clinically relevant.
- **FGFR2** amplification levels (CNV <4 or ≥4 and CNV <10 or ≥10) are clinically relevant.
- **FGFR2** amplification levels (CNV <4 or ≥4 and CNV <10 or ≥10) are clinically relevant.